Orodispersible Levitra tablet launched for ED

Levitra is the first ED drug to be launched as an orodispersible formulation
Levitra is the first ED drug to be launched as an orodispersible formulation

Erectile dysfunction treatment vardenafil (Levitra) is now available as an orodispersible tablet.

Placed on the tongue approximately 60 minutes before sexual activity, the 10mg tablet rapidly dissolves without the need to take separate liquid.

Efficacy of the orodispersible tablet was demonstrated in two 12-week studies of identical design, POTENT I and POTENT II.

The 2 studies enrolled a total of 882 men who had had erectile dysfunction for more than 6 months. In both studies, the orodispersible tablets were significantly superior to placebo for all efficacy measures (p<0.0001 for all), both primary (International Index of Erectile Function and Sexual Encounter Profile questions 2 and 3) and secondary.

Levitra orodispersible tablets are not indicated for initiation of vardenafil treatment in patients with mild hepatic impairment.

View Levitra drug record

Further information: Bayer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Free resources on MIMS Learning keep you updated on COVID-19

Free resources on MIMS Learning keep you updated on COVID-19

MIMS Learning has a range of free resources for healthcare...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...